Rigel Pharmaceuticals Inc. at 35th Annual J.P. Morgan Healthcare Conference 2017 (Replay)
January 11, 2017 at 2:00 p.m. PT
Rigel’s current clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in a number of indications. The company completed and reported results from two Phase 3 clinical studies in chronic immune thrombocytopenia, or ITP
, in August and October 2016. Rigel is also conducting a Phase 2 clinical trial with fostamatinib in autoimmune hemolytic anemia (AIHA)
and a Phase 2 clinical trial for IgA nephropathy (IgAN)
. In addition, Rigel has two oncology product candidates in Phase 1 development with partners BerGenBio AS
and Daiichi Sankyo
Recent NewsMore »
|01/05/17||Rigel Provides Business Updates and Preliminary Data in IgA Nephropathy|
|Announces Presentation at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco
SOUTH SAN FRANCISCO, Calif., Jan. 5, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, will present a review of products in development and a financial overview at the upcoming 35th Annual J.P. Morgan Healthcare Conference in San Francisco on January 11, 2017, at 2pm PST (see webcast details below)... |
|11/10/16||Rigel to Present at Jefferies 2016 London Healthcare Conference|
|SOUTH SAN FRANCISCO, Calif., Nov. 10, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the Jefferies 2016 London Healthcare Conference on Wednesday, November 16th at 11:20am GMT.
To access the live webcast of the presentation or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes prior ... |
|11/01/16||Rigel Announces Third Quarter 2016 Financial Results and Provides Company Update|
|Conference Call and Webcast Today at 5:00 PM Eastern Time
SOUTH SAN FRANCISCO, Calif., Nov. 1, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the third quarter and nine months ended September 30, 2016.
During the third quarter of 2016, Rigel accomplished a number of noteworthy milestones, most importantly, the announcement of topline results for its FIT Phase 3 clinical studies of fostamatinib in ITP. Additionally, the company undertoo... |
Upcoming EventsMore »
There are currently no events scheduled.
|Sign up to receive e-mail alerts whenever Rigel Pharmaceuticals Inc. posts new information to the site. Just enter your e-mail address and click Submit.|